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Background: The epithelial-to-mesenchymal transition (EMT) process results in a loss of cell-cell adhesion, increased
cell mobility, and is crucial for enabling the metastasis of cancer cells. Recently, the enzyme SIRT1 has been implicated
in a variety of physiological processes; however, its role in regulating oral cancer metastasis and EMT is not fully
elucidated. Here, we propose a mechanism by which the enzyme sirtuin1 (SIRT1) regulates the EMT process in oral
cancer by deacetylating Smad4 and repressing the effect of TGF-β signaling on matrix metalloproteinase-7 (MMP7).
Methods: The roles of SIRT1 in tumor cell migration/invasion and metastasis to the lungs were investigated using the
Boyden chamber assay and orthotopic injections, respectively. RNA interference was used to knockdown either SIRT1
or Smad4 expression in oral squamous cell carcinoma (OSCC) cell lines. Immunoblotting, zymographic assays, and
co-immunoprecipitation were used to examine the effects of SIRT1 overexpression on MMP7 expression and activity, as
well as on SIRT1/ Smad4 interaction.
Results: We found that compared with normal human oral keratinocytes (HOKs), SIRT1 was underexpressed in OSCC
cells, and also in oral cancer tissues obtained from 14 of 21 OSCC patients compared with expression in their matched
normal tissues. Overexpression of SIRT1 inhibited migration of OSCC cells in vitro, as well as their metastasis to the lung
in vivo. Furthermore, up-regulation of SIRT1 in metastatic OSCCs significantly inhibited the migration and invasion
abilities of OSCC cells, while concomitantly increasing the expression of E-cadherin, and decreasing the expressions of
mesenchymal markers. We also identified Smad4, a TGF-β-activated transcription factor, as a direct target protein for
SIRT1. Overexpression of SIRT1 in OSCC cells led to decreased levels of acetylated Smad4, and inhibition of
TGF-β-induced signaling. By associating and deacetylating Smad4, SIRT1 enzyme can influence MMP7 expression,
MMP enzyme activity, and consequently, cell migration, invasion, and tumor metastasis in OSCCs.
Conclusions: These findings provide a valuable insight into the potential role of the SIRT1 enzyme in regulating
cell migration and invasion in oral squamous cell carcinoma. Our findings suggest the SIRT1/Smad4/MMP7
pathway as a target for oral cancer driven by EMT.
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Oral cancer is the sixth most common human cancer
worldwide, and >90% of oral malignancies are squamous
cell carcinomas [1]. Oral squamous cell carcinoma
(OSCC) accounts for >95% of all head and neck cancers,
and can develop from oral precancerous lesions such as
leukoplakia and erythroplakia [1-3]. The incidence of
oral cancer in Taiwan has increased 30% during the last
5 years, and the overall mortality rate has increased 25%.
Males aged 30–49 years have the highest rate of mortal-
ity due to oral cancer [4,5]. More than 50,000 new cases
of oral cancer are diagnosed annually, and the overall
5-year survival rate for OSCC patients during the last 2
decades has consistently remained between 34% and
62.7% [5-7]. It was recently reported that the cervical
lymph node is a critical prognostic indicator of the
clinical course of OSCC, and that patients with cervical
lymph node metastasis usually have lower survival rates
[8-10]. Similar to other cancers, oral cancer metastasis
occurs after a localized tumor progresses to an advanced
stage [11]. Therefore, an understanding of the molecular
mechanism which regulates OSCC metastasis can provide
information important for developing new drugs and
guidelines for treating metastasized oral cancers. Cancer
metastasis is accelerated by an epithelial to mesenchymal
transition (EMT) process resulting in increased cell migra-
tion and invasion, cell-substrate adhesion, intravasation
and extravasation, as well as increased cell survival. EMT
plays an important role in cancer invasion and metastasis,
during which epithelial cells lose their cell-adhesive prop-
erties, repress E-cadherin expression, and increase their
levels of mobility, matrix metalloproteinases (MMPs), and
expression of mesenchymal markers [12-14]. E-cadherin is
a cell-cell adhesion molecule expressed predominantly
by epithelial cells. Reduction or loss of E-cadherin is
considered a hallmark event of EMT, which initiates a
series of signaling events and a major reorganization of
the cell cytoskeleton [15,16]. Concomitant with the loss
of E-cadherin and actin reorganization, cells undergoing
EMT acquire a mesenchymal phenotype that becomes
apparent by the expression of mesenchymal cytoskeletal
proteins such as vimentin, and increased deposition of
extracellular matrix proteins by MMPs. These extracellu-
lar matrix components stimulate integrin signaling and
facilitate cell migration [17,18]. Furthermore, decreased
expression of E-cadherin during EMT is accompanied by
increased expression of N-cadherin, which renders the cell
more motile and invasive [19-21]. These different events
result in a loss of apical-basal polarity, after which, the
cells acquire a front-back polarity that allows them to
migrate in a directional fashion. The increased MMP
expression and activity allows the cells to degrade extra-
cellular matrix proteins, permitting their delamination and
escape from their epithelial components [22]. In cancer,epithelial tumor cells become more invasive after under-
going EMT, and enter the circulatory system through
intravasation. This results in their dissemination to loci
distal from the primary tumor. Hence, elucidating the
molecular mechanism which regulates expression of
E-cadherin, N-cadherin, and MMPs, has become pivotal
for understanding cancer invasion and metastasis.
Sirtuins are nicotinamide adenine dinucleotide (NA
D+)-dependent histone deacetylases [23]. Human homo-
logues of the Sir2 gene are found in yeast, and are
considered a critical link to longevity, as they prolong
the cellular replication cycles of Saccbaromyces Cerevi-
siae and Caenorbabditis elegans [24,25]. Several types
of sirtuin enzymes have been identified (SIRT1-7), and
their enzymatic activities are regulated by the ratio of
NAD+ to NADH; high NAD+ levels activate sirtuin
enzymes, and conversely, high NADH levels inhibit their
activity [26]. Due to their abilities to deacetylate both
histone and non-histone substrates, sirtuin enzymes have
roles in regulating multiple cellular and physiological
processes, including diabetes, inflammation, neuro-
degenerative diseases, stress responses, cell survival,
metabolism, aging, and longevity [27-30]. Sirtuin enzymes
are widely expressed in normal tissues. SIRT1 localizes
primarily in the nucleus, along with SIRT6 and SIRT7;
whereas SIRT2 is in the cytoplasm, and SIRT3, SIRT4,
and SIRT5 are localized in the mitochondria [31].
SIRT1 is a class III histone deacetylase capable of dea-
cetylating lysine residues on nuclear proteins, which is
thought to affect their stability, transcriptional activity,
and translocation. Recently, SIRT1-mediated deacetyla-
tion of nuclear proteins such as p53, FOXO, and Ku70
[32-34], has been reported to promote cell survival.
Roles for SIRT1 in skin, colon, breast, and lung cancers
have been demonstrated through its affects on one or
more of the aforementioned nuclear proteins [35-39].
Additionally, SIRT1 can regulate vascular endothelial
homeostasis by controlling angiogenesis and vascular
function [40], and also regulates the transcription of
numerous genes by interacting with transcription fac-
tors. For example, upon recruitment to chromatin by
transcription factors, SIRT1 deacetylates histones to
suppress gene transcription [28,41,42]. Despite evidence
for SIRT1 involvement in a variety of cell regulatory and
physiological processes, the role of SIRT1 in regulating
oral cancer metastasis and EMT remains enigmatic. In
this study, we investigated the involvement of SIRT1 in
EMT as it occurs in oral cancer metastasis. We found
that SIRT1 expression was substantially downregulated in
OSCC cell lines, and was also widely attenuated in OSCC
tumors as compared with expression in paired normal
tissues. SIRT1 overexpression repressed the EMT process
in oral cancers and blocked migration of OSCC cells
in vitro. In contrast, knockdown of SIRT1 in oral cancer
Chen et al. Molecular Cancer 2014, 13:254 Page 3 of 19
http://www.molecular-cancer.com/content/13/1/254cells enhanced EMT and cancer metastasis in vitro. We
also show that SIRT1 regulates expression of the epithelial
marker E-cadherin, as well as the mesenchymal markers
vimentin and N-cadherin. Moreover, we found that SIRT1
targets Smad4 to reduce EMT and MMP7 expression.
Finally, we show that SIRT1 overexpression reduced the
invasiveness and metastasis of oral cancer cells in im-
munodeficient mice. In summary, our data show that
SIRT1 inhibited the EMT process in oral cancer by dea-
cetylating Smad4 and repressing expression of MMP7.
These results suggest a role for SIRT1 as a metastasis
suppressor in oral cancer.
Results
Variable levels of SIRT1 expression and its activity
To evaluate the role of SIRT1 in regulating oral cancer
metastasis and EMT, we first investigated whether SIRT1
expression in normal primary human oral keratinocytes
(HOKs) differed from that in OSCC cells. We examined
the SIRT1 mRNA and protein levels in 5 OSCC cell lines
(HSC3, OECM1, OC3, SCC4, and SCC25) and compared
them with their levels in HOK cells (Figure 1A). We found
that both the transcription and translation products of
SIRT1 were more highly expressed in HOKs compared to
their expressions in various OSCC cell lines. Next, we iso-
lated the nuclear fractions of HOK cells and OSCC cells,
immunoprecipitated the endogenous SIRT1, and tested
for its deacetylase activity. Surprisingly, we found that
all OSCC cell lines had drastically lower levels (~50%)
of SIRT1 activity compared with those in HOK cells
(Figure 1B). Additionally, we examined 21 pairs of oral
normal and cancer tissues obtained from OSCC pa-
tients and tested them for SIRT1 mRNA expression. We
found that SIRT1 mRNA levels were drastically underex-
pressed (P = 0.0024) in 14 of the 21 OSCC samples com-
pared with expression in their matched normal tissues
(Figure 1C and D). We next used immunohistochemistry
(IHC) techniques to analyze the levels of SIRT1 expression
in clinical samples. We found that 15 pairs of matched
normal and tumor tissue samples obtained from 21 OSCC
patients showed significantly higher SIRT1 expression in
the normal tissue as compared to the tumor tissue
(Figure 1E). These results suggested that SIRT1 might
exclusively be responsible for the development of oral
cancer, and that decreasing SIRT1 expression and enzyme
activity may increase an individual’s susceptibility to
tumorigenesis and metastasis of oral cancer.
SIRT1 represses migration and invasion of OSCC cells
through its deacetylase activity
SIRT1 is a histone/protein deacetylase, and numerous
studies have reported SIRT1 involvement in the regula-
tion of various processes through its deacetylase activity
[41]. Therefore, we conducted Boyden Chamber assaysto determine whether the deacetylase activity of SIRT1
would suppress the migration and invasion of oral can-
cer cells. As expected, activation of SIRT1 in OSCC cell
lines by resveratrol (RSV; a SIRT1 agonist) suppressed
the migration of OECM1 and HSC3 cells. In contrast,
an SIRT1 antagonist (sirtinol) was completely ineffective
in suppressing cell migration, and greatly increased oral
cancer cell metastasis in vitro (Figure 2A). Next, we
ectopically expressed SIRT1 in OSCC cell lines OECM1
and HSC3, thus taking advantage of their low SIRT1
expression. As shown in Figure 2B, overexpression of
SIRT1 induced by transient transfection significantly
blocked the migration and invasion of OSCC cells, as
compared with the migration and invasion behaviors
shown by pEGFP-C1 vector only transfected control
cells. Furthermore, we also knocked down SIRT1 expres-
sion in both OSCC cell lines with or without siRNA
oligonucleotides, and found that knockdown cells dis-
played significantly increased migration and invasion abil-
ities (p <0.05), compared with those shown by Scrambled
control cells. These results indicated that the migration
and invasion of OSCC cells were significantly suppressed
by exogenous overexpression of SIRT1, while repression
of SIRT1 by small interfering RNA molecules increased
the metastatic potential of OSCC cells. Thus, SIRT1 acti-
vation appears to be tightly correlated with cell migration
and invasion ability, and SIRT1 might be an important
regulator of migration and invasion in oral cancer cells.
SIRT1 regulates expression of epithelial and mesenchymal
protein markers
Previous studies have described E-cadherin as a well-
established hallmark of EMT [14]. Therefore, we sought
to determine whether E-cadherin expression is altered in
OSCC cell lines. Surprisingly, we found that SIRT1 and
E-cadherin were overexpressed in HOK cell lines com-
pared to their expression in both OSCC cell lines. In
contrast, SIRT1, as well as mesenchymal marker pro-
teins N-cadherin and vimentin, were inversely expressed
at the basal condition in normal HOK cells, and also in
the OSCC cell lines OECM1 and HSC3 (Figure 3A). We
next investigated the possible regulation of E-cadherin,
N-cadherin, and vimentin expression by SIRT1, by using
siRNA oligonucleotides to knock down SIRT1 expres-
sion in HOK cell lines, and found that SIRT1 silencing
clearly down-regulated E-cadherin expression. Addition-
ally, the deletion of SIRT1 led to significantly increased
N-cadherin and vimentin expression in knockdown
HOK cells. A similar reciprocal relationship was ob-
served in the case of SIRT1 overexpression in OECM1
cells, which showed increased E-cadherin expression
(Figure 3B and C). Moreover, we also determined the
expression of certain mesenchymal markers important
for EMT. Transfection of OSCC cells with an SIRT1
Figure 1 Variable levels of SIRT1 expression and its activity were noted among normal cells (HOK) and OSCCs. (A) Quantitative RT-PCR
(qRT-PCR) and western blotting revealed the expression levels of SIRT1 in HOK and OSCC cell lines. (B) Specific activities of SIRT1 in HOK and OSCC cell
lines were determined by enzyme assays. Equal amounts of cellular SIRT1 protein (250 ng) were immunopurified with antibodies against SIRT1, and
SIRT1 enzyme activity assays were performed with a SIRT1 Fluorometric Kit, using standard protocols provided by the supplier. (C and D)
qRT-PCR revealed significant underexpression (P = 0.0024 ) of SIRT1 in 14 of 21 OSCC samples compared with their matched normal tissues.
(E) The expression levels of SIRT1 in the normal and tumor tissues of 21 OSCC patients as determined by IHC. The IHC semi-quantitative
score was derived by two independent pathologists who multiplied the staining intensity by the percent of tumor cells stained. IHC scores
for each core of a specimen were averaged (n = 21) and statistically analyzed (*, p <0.05). Each data point represents the mean value ± SD
obtained from at least three independent experiments.
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subsequently reduced the expression of the mesenchy-
mal proteins N-cadherin and vimentin. Together, these
data indicated that SIRT1 may play a role in regulating
epithelial and mesenchymal protein expression.SIRT1 represses expression of MMP7 in OSCC cells
Similar to the metastatic mechanism of other cancers,
oral cancer metastasis requires an extensive remodeling
and degradation of the extracellular matrix, partially via
increased expression of matrix metalloproteinases (MMPs)
Figure 2 SIRT1 activation prevents oral cancer metastasis. (A) OSCC cells (105) were treated with 50 uM resveratrol (RSV; an SIRT1 agonist)
and 10 uM sirtinol (an SIRT 1 antagonist) for 24 h, respectively. (B) Transient transfection of pEGFP-SIRT1 significantly inhibited the migration and
invasion of OECM1 and HSC3 cells, which were rescued by siSIRT1. Transient transfected cells (overexpression-SIRT1 or knockdown SIRT1) were
seeded in a 24-well chemotaxis chamber (1 × 104 cells/well) and incubated for 24 h with complete culture medium added in the lower chamber.
Cell migration and invasion by Boyden chamber assays. Each data point represents the mean ± SD from at least three independent experiments.
The asterisk indicates as statistically significant difference (*, p <0.05) compared to the pEGFP-C1 vector control or scrambled siRNA control.
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with oral cancer metastasis and EMT [44,45], which
suggests that the SIRT1 overexpression might affect
MMP7 expression in OSCCs. We thus examined the
effect of transiently expressed SIRT1 on OSCC cell lines
by using a GFP-tagged SIRT1 expressing vector. We
found that MMP7 transcription and translation were
significantly decreased in SIRT1-overexpressing cells
compared with their levels in control cells (Figure 4A
and B). We also compared the enzymatic activity of
MMP7 in SIRT1 overexpressing and silencing OSCC cells.
When MMP7 activity was assayed by casein zymography,the activity in the media from SIRT1-overexpressing
OECM1 cells was significantly lower than that in media
from mock-transfected cells. In contrast, SIRT1 silen-
cing produced a significant increase in MMP7 activity
(Figure 4C). This activity change is probably due to the
difference in the protein levels, as determined by ELISA
and immunoblotting with anti-MMP7 antibody. The
levels of MMP7 secreted into the media of OSCC cell
lines were also estimated by ELISA at 48 h after trans-
fection with a SIRT1 expression vector or siSIRT1. We
found that MMP7 secretion by SIRT1-overexpressing
OSCC cells was significantly suppressed (p <0.05) as
Figure 3 Expression of epithelial and mesenchymal protein markers are regulated by SIRT1 in HOK and OSCC cells. (A) Western blotting
revealed the expression levels of epithelial and mesenchymal protein markers in HOK and OSCC cell lines. Equal amounts of cell protein (20 ug)
were immunoblotted with antibodies against SIRT1, E-cadherin, vimentin, N-cadherin, and β-actin. (B) Loss of SIRT1 increased expression of
endogenous mesenchymal protein markers. Western blotting revealed expression of SIRT1 and EMT markers in HOK cells with or without
siSIRT1. (C) Ectopic expression of SIRT1 increased expression of E-cadherin and reduced expression of vimentin and N-cadherin. Equal amounts of
protein (20 ug) from OECM1 cells were transient transfected with pEGFP-SIRT1 or vector alone (pEGFP-C1) and analyzed by Western blot.
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contrast, SIRT1 silencing in oral cancer cells resulted in
a significant induction of MMP7 secretion. A similar
result was seen in western blot experiments, where
MMP7 secretion was significantly suppressed by ex-
ogenously produced overexpression of SIRT1 in both
OSCC cell lines, whereas repression of SIRT1 by SIRT1
silencing increased MMP7 secretion (Figure 4D). We
further studied the mechanism by which SIRT1 regu-
lates MMP7 expression by determining whether SIRT1
could associate and deacetylate MMP7. Immunoprecip-
itations performed with an anti-SIRT1 or anti-MMP7
antibody in OSCC cells failed to identify any endogenous
molecular binding between SIRT1 and MMP7 (data not
shown). This result indicated that SIRT1 could influence
MMP7 expression, secretion, and activity; and subse-
quently, cell migration, invasion, and metastasis through
its target proteins.SIRT1 deacetylates Smad4 in OSCC cells
MMP7 has been shown to be important for accelerating
cancer invasion and metastasis in multiple tissues [46],
but does not seem to be necessary for invasion or fibrosis
of colon cancer, in which Smad4-dependent transforming-
growth-factor (TGF)-β family signaling is blocked [47].
Thus MMP7 is not needed for tissue invasion in Smad4-
deficient adenocarcinomas. Additionally, a previous study
revealed that SIRT1 directly interacts with and deacety-
lates the negative regulator of TGF-β signaling, Smad7, to
destabilize the protein in a mesangial kidney cell line [48].
We therefore postulated that SIRT1 might affect MMP7
through its interactions with Smad4, a TGF-β-activated
transcription factor. To test this hypothesis, we first used
an immunoprecipitation assay to examine the ability of
SIRT1 to bind to Smad4. Our results showed that while
SIRT1 directly interacted with Smad4 in vivo, it did
not interact with Smad2 protein (Figure 5A). We also
Figure 4 SIRT1 down-regulates expression and activity of MMP7. (A) qRT-PCR revealed the expression levels of MMP7 in OSCC cell lines after
transient transfection with pEGFP-SIRT1 or vector alone (pEGFP-C1). Each data point represents the mean ± SD from at least three independent
experiments. The asterisk indicates statistically significant difference (*, p <0.05) comparing to the control. (B) The MMP7 protein level was
assessed by immunoblotting with anti-MMP7 antibody and GAPDH. MMP7 proteins in the cell homogenates were evaluated. (C) MMP7 activity
was assayed by casein zymography. MMP7 activities in the cell media were compared between SIRT1-overexpressing or silencing OECM1 cells.
(D) MMP7 concentrations and protein levels in OSCC cell media were assessed by ELISA and immunoblotting with anti-MMP7 antibody and
GAPDH. Cell culture media were collected and concentrated from SIRT1-overexpressing or silencing OSCC cell lines.
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examine the ability of Smad4 to bind SIRT1. Western
blotting detected SIRT1 in the Smad4 immunoprecipitate
from nuclear extracts of OSCCs. We next examined
whether SIRT1 could directly deacetylate Smad4. We
immunopurified endogenous Smad4 from SIRT1 knock-
down OECM1 and HSC3 cells, and probed western blots
with antibodies to Smad4 proteins or acetylated-lysine
(Figure 5B). This experiment showed that SIRT1 silencingsignificantly increased the level of acetylated Smad4 in
SIRT1 knockdown OSCC cells. Furthermore, we also
confirmed the acetylation levels of Smad4 in OECM1
and HSC3 cells at 0, 16, 24, and 48 h after transfection
with the SIRT1 expression vector. Overexpression of
SIRT1 clearly reduced the acetylation levels of Smad4,
while knockdown of SIRT1 increased the acetylation
levels (Figure 5C and Additional file 1: Figure S1A).
These results suggest that while SIRT1 associates with
Figure 5 SIRT1 interacts with Smad4. (A) Smad4 binds to SIRT1 in OSCC cells. Nuclear extracts from OECM1 and HSC3 cells were
immunoprecipitated using a SIRT1 or Smad4 antibody, and analyzed by western blot using antibodies against Smad2, Smad4, and SIRT1. (B)
Knock down of SIRT1 increased endogenous Smad4 acetylation. Acetylated endogenous Smad4 proteins in OSCC cells with or without siSIRT1
were then immunopurified with Smad4 antibody. Western blots were probed with SIRT1, acetylated-Lysine (Ac-K), and Smad4. (C) Ectopic expression
of SIRT1 reduced levels of acetylated Smad4. Equal amounts of protein (20 ug) from OECM1 cells were transient transfected with pEGFP-SIRT1 or vector
alone (pEGFP-C1) for 0–48 h and analyzed by Western blot. (D) Western blotting revealed the expression and acetylation levels of endogenous Smad4
in OECM1 cell lines transient transfected with pEGFP-SIRT1 or vector alone (pEGFP-C1) for 24 h, and treated with TGF-β 5 ng/mL for 48 h. Western blots
were probed with SIRT1, acetylated-Lysine (Ac-K), and Smad4.
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is not required for Smad4 protein expression.
Because Smad4 is a transcription factor that responds
to TGF-β signaling, we next investigated the expression
levels of Smad4 in SIRT1-overexpressing OECM1 and
HSC3 cells following TGF-β stimulation (Figure 5D and
Additional file 1: Figure S1A). We observed that levels
of endogenous Smad4 protein in SIRT1-overexpressing
or mock-transfected cells were increased ~2-fold after
48 h of TGF-β stimulation. Surprisingly, the acetylation
level of Smad4 was highly increased by TGF-β induction,
while overexpression of SIRT1 significantly reduced the
acetylation level of TGF-β induced Smad4 in OSCCs.
Taken together, suggest that SIRT1 functionally interacts
with Smad4 in vivo, resulting in the deacetylation of
Smad4 and inhibition of TGF β-induced signaling.SIRT1 regulates MMP7 expression through deacetylating
Smad4
Previous studies have suggested that Smad4 may regulate
MMP7 expression in cancer, and we therefore examined
the effect of transiently silencing Smad4 in oral squamous
carcinoma cells by transfected siRNA. Our results showed
that MMP7 mRNA expression reduced, and a similar
result was seen in a Western blot experiment. SIRT1
silencing significantly downregulated MMP7 protein
expression in both OSCC cell lines (Figure 6A and B).
We then collected and concentrated cell culture media
from Smad4-silencing cells. A subsequent ELISA analysis
of the media showed that MMP7 secretion was signifi-
cantly decreased in siSmad4 OSCC cells compared with
secretion in scrambled control OSCC cells. Assays of
MMP7 concentrations and activity by casein zymography
Figure 6 Smad4 regulates MMP7 expression in OSCCs. (A) Quantitative RT-PCR expression of the MMP-7 gene in OECM1 and HSC3 cell lines
with or without siSmad4. (B) Western blotting revealed the expression levels of MMP7 in OSCC cells with or without siSmad4. (C) MMP7
concentrations and activity in OECM1 and HSC3 media were assessed by ELISA and casein zymography, respectively. Cell culture media were
collected and concentrated from Smad4 silencing OSCC cell lines. Each data point represents the mean ± SD of at least three independent
experiments. The asterisk indicates as statistically the significant difference (*, p <0.05) compared to control.
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the siSmad4 OECM1 and HSC3 cells was significantly
lower than that in the media of control cells, and a similar
result was shown by studies of MMP7 concentration(Figure 6C). These experiments showed that Smad4 regu-
lates and is required for MMP7 expression, secretion, and
activity in oral cancer. To address whether the SIRT1
regulation of MMP7 expression was modulated via the
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expression in SIRT1-overexpressing OECM1 and HSC3
cells following their stimulation with TGF-β. As shown in
Figure 7A and Additional file 2: Figure S2A, TGF-β stimu-
lation increased Smad4 expression and hyperacetylation of
Smad4 in both OSCC cell lines. Additionally, TGF-β also
induced expression of MMP7, which became hyperex-
pressed when Smad4 was hyperacetylated following TGF-β
stimulation. Next, we ectopically expressed SIRT1 in
OECM1 and HSC3 cell lines, and found that overexpres-
sion of SIRT1 in OSCC cells led to both decreased levels of
Smad4 acetylation, and repressed affects of TGF-β sig-
naling on MMP7. TGF-β induces MMP7 expression
which results in extracellular cleavage of E-cadherin from
the cell surface, and disruption of E-cadherin [49,50].
Therefore, we also tested the effect of E-cadherin
expression in SIRT1-overexpressing cells after they
had been pre-treated with TGF-β. Interestingly, while
TGF-β reduced E-cadherin levels in both mock-transfected
cells and SIRT1-overexpressing OSCC cells, the reductions
were much greater in SIRT1-overexpressing cells. Similarly,
MMP7 activity in mock-transfected cells was markedly
increased by TGF-β stimulation (Figure 7B and Additional
file 2: Figure S2B). In contrast, overexpression of SIRT1 in
oral cancer cells caused a significant reduction of MMP7
activity, while TGF-β stimulation was slightly reversed
the increase in MMP7 activity (p <0.05). This change
was closely related to the deacetylation levels of Smad4,Figure 7 SIRT1 represses the expression of MMP7 by deacetylating Sm
Smad4, MMP7, and E-cadherin in OECM1 cell lines transient transfected wit
TGF-β (5 ng/mL) for 48 h. (B) MMP7 activities of SIRT1-overexpressing or m
treatment with or without (TGF-β 5 ng/mL) for 48 h. (C) SIRT1 repressed ex
revealed the expression and acetylation levels of endogenous Smad4 from fla
with or without siSIRT1, and then purified by Flag beads. Western blots wereand might be responsible for the reduced efficiency
of TGF-β signaling in regulating MMP7 expression.
Recently, several acetylation sites in Smad4 isolated from
the nucleus have been identified by high-resolution mass
spectrometry [51]. However, the acetylation site in Smad4
which directly interacts with SIRT1 remains unknown.
We generated a flag-tagged Smad4 WT, Smad4-K37R,
and Smad4-K428R mutant OECM1 cells, and analyzed
their acetylation levels. After immunopurifying ectopically
expressed Flag-tagged Smad4 proteins from OECM1
mutants after knock down of SIRT1, we found that the
acetylation mimetic mutant Smad4K37R had a signifi-
cantly decreased level of acetylation compared to the
wild-type Smad4. Whereas K428R substitution greatly
increased acetylation to levels similar to those observed
in wild-type Smad4 (Figure 7C). Together, these obser-
vations indicated that TGF-β stimulation increased
Smad4 and MMP7 expression, and SIRT1 deacetylated
Smad4 in vivo; additionally, K37 was the primary target
of SIRT1, resulting in decreased MMP7 expression and
activity. Thus, SIRT1 participates in regulation of MMP7
activity and expression by deacetylating K37 of Smad4,
and repressing the effect of TGF-β signaling in oral cancer.
Overexpression of SIRT1 inhibits lung metastasis of OSCC
cells
Our results showed that SIRT1 inhibits the EMT process
in cancer by deacetylating Smad4 and repressing thead4 in OSCCs. (A) Western blotting reveled the expression levels of
h pEGFP-SIRT1 or vector alone (pEGFP-C1) for 24 h, and treated with
ock-transfected OECM1 cells were assayed by casein zymography after
pression of MMP7 by deacetylating K37 of Smad4. Western blotting
g-tagged Smad4 WT, Smad4-K37R, and Smad4-K428R OECM1 mutants
probed with flag, acetylated-Lysine (Ac-K), and MMP7.
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tulated that overexpression of SIRT1 may suppress can-
cer cell metastasis in vivo. We used a floor-of-the mouth
murine model in SCID mice to determine whether
SIRT1 inhibits cancer cell metastasis in vivo. OECM1
cells were stably transfected with the vector alone
(pEGFP-C1) or a vector inducing overexpression of
SIRT1 (pEGFP-SIRT1). Ten SCID mice used in the
floor-of-the mouth model were injected with OECM1
cells. Two mice were injected with PBS (controls), four
were injected with control vector, and four with SIRT1-
overexpressing OECM1 cells. As shown in Figure 8,
With the exception of PBS control mice, all mice grew
similar tumors in the floor-of-the mouth (Figure 8).
Upon dissection, the tumors showed multiple foci and
poorly differentiated SCCs with prominent lymphovascu-
lar invasion at the orthotopic injection site. Among mice
injected with vector alone (n = 8) ~75% showed lung
metastasis, while ~25% of mice injected with SIRT1-
overexpressing vector (n = 8) showed lung metastasis.Figure 8 Overexpression of SIRT1 represses lung metastasis. SIRT1 inh
model with SCID mice. Six-week-old male CB17-SCID mice were anesthetiz
mL) stably expressing SIRT1 expression plasmid or vector alone. All survivin
tissues were removed, fixed, paraffin-embedded, serially sectioned, and sub
(IHC) staining (magnification, ×100). Upper two panels show results of H&E
The lung metastasis index was calculated as follows: metastatic tumor area
metastasis index is indicated as the mean ± SD. The asterisk indicates as staThese results showed that stable overexpression of
SIRT1 significantly suppressed lung metastasis of
OECM1 cells (p <0.05), resulting in fewer metastatic
foci and smaller nodules in the lung. We also examined
the tumor region of the extracted tissue by ICH with
anti-Smad4 polyclonal antibody, and found higher levels
of Smad4 expression in the lung tissue extracted from
mice in the vector-only control group. The results indi-
cated that overexpression of SIRT1 in OECM1 cells led
to significantly suppressed lung metastasis in the floor-
of-the mouth murine model.
Discussion
In this study, we demonstrated that SIRT1 suppresses the
EMT process in oral squamous cell carcinoma cells by
deacetylating Smad4 and repressing MMP7 expression. It
was previously shown that SIRT1 helps regulate a variety
of physiological processes by interacting with nuclear
proteins [28,52-56]. Despite its implied involvement in
a variety of physiological processes, the regulatory roleibited cancer cell metastasis in vivo in a floor-of-the mouth murine
ed and injected with human OSCC cell line OECM1-S1 (2.5 × 105 cells/
g mice were sacrificed after 42 days, and orthotopic tumor and lung
jected to hematoxylin and eosin (H&E) and immunohistochemical
staining and lower two panels show results of Smad4 IHC staining.
s/total lung area. T, tumor tissue; M, metastatic nodule. Quantitative
tistically significant difference (*, p <0.05) compared to the control.
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In this study, we demonstrated for the first time that
SIRT1 is a critical negative regulator of EMT and cell
migration in vitro, and also of tumor metastasis in vivo
(immunodeficient mouse model). Our studies showed
that compared with expression in HOK cells, SIRT1 was
overexpressed in both OSCC cell lines, and a similar
result was found in an enzyme activity experiment. We
also found that activation of SIRT1 in oral squamous
cell carcinoma resulted in decreased cell migration and
invasion. Therefore, we propose a molecular mechanism
whereby SIRT1 regulates cell migration by interacting with
and deacetylating TGF-β-inducing transcription factor
Smad4 to suppress MMP7 expression. We found that
increased levels of SIRT1 in oral squamous cell carcinoma
tissue contributing to decreased Smad4 acetylation and
repressed MMP7 activity. In addition, our findings
revealed that an absence of SIRT1 led to Smad4 hyper-
acetylation, MMP7 hyperexpression, and degradation
of E-cadherin on the cell surface. These events resulted
in release of β-catenin from the E-cadherin-β-catenin
complex junctions leading to the nucleus, and pro-
moted metastasis of OSCC cells (Figure 9). In addition
to the in vitro data showing that up-regulation of
SIRT1 led to low cellular invasiveness and migratory
abilities, SCID mice with SIRT-overexpressing OSCC
cells showed significantly less lung metastasis com-
pared to control mice. The EMT process represents
the critical event in the transition from early stage toFigure 9 Schematic representation of SIRT1 effects on metastasis of o
by deacetylating Smad4 and repressing the effect of TGF-β signaling on Minvasive carcinoma [11,57], and E-cadherin downregu-
lation is well associated with poor prognosis, lower
survival, and higher rates of metastasis in OSCC
patients [58-61]. Our results showed that SIRT1 overex-
pression reduced oral cancer cell migration and metas-
tasis, and these effects were largely independent of any
general effects of SIRT1 on oral cancer growth and sur-
vival. Taken together, these data suggest that SIRT1
may prevent oral cancer metastasis by blocking the
EMT process.
Interestingly, our results differed from previous reports
which indicated that SIRT1 serves as a positive regulator of
epithelial-mesenchymal transition, the metastatic growth of
prostate cancer cells [62], and is associated with malignancy
in chronic myelogenous leukemia [63]. Additionally SIRT1
involvement has also been suggested in epigenetic silencing
of DNA-hypermethylated tumor suppressor genes in breast
cancer cells [64]. Recently, SIRT1 has been shown to be an
important target of miR-200 in regulating breast cancer cell
migration [65,66]. Additionally, SIRT1 is highly expressed
in various cancers [35,67] such as prostate cancer, and high
levels of SIRT1 expression are associated with a poor prog-
nosis in lung cancer, breast cancer, gastric carcinomas, and
B-cell lymphoma [68-71]. In prostate cancer, SIRT1 was
shown to enhance cell migration and metastasis by
cooperating with EMT transcription factor ZEB1 to
suppress E-cadherin transcription. In lung cancer, the
SIRT1 activator compound 1720 was shown to increase
lung metastasis of implanted breast cancer cells,ral cancer. SIRT1 reduced cell migration and invasion in oral cancer
MP7.
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metastasis to the lung [72]. Moreover, miR-200 nega-
tively regulated SIRT1 expression and inhibited the
EMT process in normal mouse mammary epithelial
cells [65]. However, the role of SIRT1 in tumorigenesis
remains controversial, and may depend on the tumor
type. A recent report showed that enhanced SIRT1
expression in a β-catenin-dependent mouse model of
colon cancer inhibited intestinal-tumor formation, thereby
indicating that the effects of SIRT1 might vary in different
tumor models, and depend on the presence of appropriate
downstream targets [73]. Moreover, SIRT1 was shown to
protect against gut carcinomas in APCmin mice [73], as
well as inhibit tumorigenesis in p53+/− mice [74,75]. Wang
et al. found that Sirt1+/−; p53+/− mice develop tumors in
multiple tissues, and activation of SIRT1 by resveratrol
reduces tumorigenesis. Moreover, several independent
investigations have found reduced levels of SIRT1 in
Sirt1+/−; p53+/− mice as compared to normal controls, and
suggested SIRT1 as an important antagonist of EMT in
various types of cancer cells [76-78]. In lung cancer, SIRT1
down-regulation by hypoxia in a SUMOylation-dependent
manner promotes EMT, and eventually leads to tumor
metastasis. This result supports the hypotheses that SIRT1
activation ameliorates lung cancer metastasis in vitro and
in vivo by blocking the entry of pre-cancerous cells into
EMT [76]. Additionally, SIRT1 has been shown to sup-
press the EMT process in metastasizing breast cancer
cells, and the development of fibrosis in organs following
their implantation into nude mice. A reduction in SIRT1
levels was shown to promote the metastasis of breast
epithelial cells in an orthotopic model of breast cancer, as
well as increase the motility of the epithelial cells [78].
Furthermore, while EMT can be induced in both breast
and kidney epithelial cells in vitro, this induction is
repressed by SIRT1 [78]. A previous study found that both
miR-520c and miR-373 suppressed SIRT1 mRNA transla-
tion, leading to activation of the Ras/Raf/MEK/Erk path-
way. Moreover, NF-κB increased MMP9 expression and
enhanced the migration of fibrosarcoma cells [79]. Our
data builds upon the results in these previous studies by
further verifying SIRT1 as a critical regulator of cancer
progression, and an important target for prevention or
possible treatment of cancer metastasis.
Similar to other cancers, oral cancer metastasis requires
degradation of the extracellular matrix via increased
expression of matrix metalloproteinases (MMPs). For
example, MMP2, 7, and 9 are overexpressed in oral
carcinoma tissue [45,80,81]. Importantly, MMP7 expres-
sion is most pronounced at the invasive front of tumors
[45,82,83], has been reported as an independent prognos-
tic factor which closely correlates with clinical stage,
tumor size, lymph node metastasis, and poor survival of
oral cancer patients. Our data also showed that MMP7expression levels and activity were significantly decreased
in OSCC cells overexpressing SIRT1 (Figure 4). Addition-
ally, we found that SIRT1 knockdown OSCC cells showed
increased MMP7 secretion and expression. We exam-
ined the interaction between SIRT1 and MMP7 in
SIRT1 knockdown OSCC cells by immunoprecipitation,
and found no direct interaction of SIRT1 with MMP7
(data not shown). A previous study showed that MMP7
was not required for malignant cell invasion in Smad4-
deficient adenocarcinomas [84]. Kitamoto et al. found
that MMP7 was required for tumor formation, but not
for the invasion of the colon cancer cells in which
Smad4-dependent TGF-β family signaling had been
blocked. Smad4 is indispensable for EMT, and RNA
interference-mediated knockdown of Smad4 expression
results in preserved E-cadherin expression [20,85-87].
Additionally, Kume et al. [48] showed that in a mesangial
kidney cell line, SIRT1 directly interacted and deacetylated
the negative regulator of TGF-β signaling, Smad7, to
destabilize the protein. Recently, numerous studies have
revealed that TGF-β stimulates the EMT process in
certain epithelial cells [22]. TGF-β drives cancer pro-
gression by inducing EMT, during which, epithelial cells
acquire a mesenchymal phenotype, leading to their
enhanced motility and invasiveness. TGF-β signaling
directly activates the expression of EMT transcription
factors, including δEF1/ZEB1, SIP1/ZEB2, and Snail/
SNAI1, which are induced by TGF-β-Smad signaling
and play critical roles in TGF-β-induced EMT [88-90].
TGF-β also binds to type II and type I transmembrane
kinase receptors, TβRII and TβRI. Following ligand
binding, TβRII phosphorylates TβRI, which activates
Smad2 and Smad3. These two activated Smad proteins
then combine with one Smad4 molecule to form trimeric
Smad complexes that translocate into the nucleus and
regulate the expression of target genes involved in the
EMT process. For example, an active complex formed
by Smad3/Smad4 and Snail can bind to the regulatory
promoter sequences of genes encoding the epithelial
junction proteins E-cadherin and occluding, leading
to TGF-β-induced repression of their expression [91].
E-cadherin downregulation decreases the strength of
cellular adhesion within a tissue, resulting in increased
cellular motility [92]. Furthermore, decreased E cadherin
expression during the EMT process is accompanied by
increased expression of N-cadherin, which renders a
cell more motile and invasive [19-21]. Additionally,
TGF-β regulates the expression and activity of extracel-
lular proteases such as matrix metalloproteinases, which
allow cells to degrade extracellular matrix proteins and
increase their migratory and invasive behaviors. [92-94].
In cancer, epithelial tumor cells become more invasive
after undergoing EMT, and access the circulatory system
through intravasation, resulting in their dissemination to
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we postulated that the effects of SIRT1 on MMP7 might
manifest via its interaction with the TGF-β-activated
transcription factor, Smad4. Our data revealed that
MMP7 expression levels and activity were significantly
decreased in the Smad4 knockdown OSCC cells (Figure 6).
Additionally, we used immunoprecipitation techniques to
confirm the occurrence of interactions between SIRT1,
Smad4, and MMP7 in OSCC cells. Interestingly, SIRT1
was shown to directly interact with Smad4 in vivo, but did
not interact with MMP7 protein (Figure 5 and Additional
file 1). We also showed that overexpression of SIRT1
repressed TGF-β-induced MMP7 expression by deace-
tylating Smad4, which becomes hyperexpressed and
hyperacetylated under conditions of TGF-β stimulation
(Figure 5D, 7A and Additional file 2). SIRT1 was shown
to affect Smad4 transcriptional activity by deacetylation,
and inhibition of Smad4 function repressed TGF-β-induced
EMT. These observations clearly show that SIRT1 might
influence MMP7 expression, secretion, and activity; and
subsequently, cell migration, invasion, and metastasis
through Smad4 deacetylation. Furthermore, we also showed
that SIRT1-overexpressing cells inhibited MMP7 secretion
and increased E-cadherin accumulation, leading to suppres-
sion of cellular invasion and migration. Our results indicate
that MMPs can mediate both the EMT process [50] and
cell metastasis [95], as well as cause nuclear translocation
of β-catenin [50,95] by proteolytic cleavage and release
of E-cadherin from the cell surface. It is therefore inter-
esting to speculate that SIRT1 maybe lead to repression
of a second pathway involved in EMT, such as the Wnt
signaling pathway.
Conclusions
In conclusion, our study identified SIRT1 as a novel
metastatic suppressor which acts through deacetylation
of TGF-β-activated transcription factor Smad4 to suppress
the effect of TGF-β signaling on MMP7 transcription,
leading to reduced migration and metastasis of OSCC
cells. SIRT1 shows potential for serving as a predictor and
biomarker for metastasis, and up-regulation of SIRT1 is a
potentially useful therapeutic strategy for inhibiting the
metastasis of oral cancers.
Methods
Cell culture and reagents
The HOK cells used in this study were cultured in oral
keratinocyte growth medium (ScienCell, Carlsbad, CA,
USA) in a 37°C incubator filled with 5% CO2, and were
routinely passaged at 90% confluence. Five human OSCC
cell lines [HSC-3 (tongue carcinoma, Japan Health Science
Research Resources Bank, JRCB 0623), OECM-1 (Gingival
carcinoma) [96], OC3 (Buccal mucosa) [97], SCC4 (tongue
carcinoma, American Type Culture Collection, ATCC®CRL1624™), and SCC 25 (ATCC® CRL1628™)] were used
in this study. HSC-3 and OC3 cells were cultured in
Dulbecco’s modified Eagle’s (DMEM) medium contain-
ing 2 mM glutamine. OECM-1 cells were maintained in
RPMI 1640 medium, while SCC4 and SCC25 cells were
cultured in DMEM/F12 medium. Each culture medium
was supplemented with 10% fetal bovine serum and 100
units/mL each of penicillin and streptomycin (Invitrogen,
Camarillo, CA, USA). All OSCC cells were maintained
at 37°C in a humidified atmosphere of 5% CO2. The SIRT1
agonist (resveratrol; RSV) and antagonists (nicotinamide
and sirtinol) were purchased from Sigma-Aldrich (St.
Louis, MO, USA).
Plasmid construction and transient transfection
The human SIRT1 coding region (GeneBank: NM_012238)
was amplified by polymerase chain reaction (PCR) using
the forward primer 5′-GTCGACATGGCGGACGAG
GCGGCCCTCGC-3′ to introduce a SalI site, and 5′-
GGATCCCTATGATTTGTTTGATGGATAGTTC-3′ to
introduce a BamHI site. The conditions for PCR were
as follows: denaturing for 30 sec at 94°C, annealing for
30 sec at 62°C and elongation for 1 minute at 72°C for
35 cycles. The full-length of SIRT1 gene was subcloned
into the constitutive mammalian expression vector
pEGFP-C1 (GeneDireX, Las Vegas, NV, USA), and
transfection was verified by DNA sequencing. Transfected
cells were seeded in 6-cm diameter dishes at 5 × 105 cells/
dish, and transfected with either pEGFP-SIRT1 or empty
vector using Lipofectamine 2000 (Invitrogen), according
to the manufacturer′s protocol. Transfected cells were
further examined in cell proliferation assays.
OECM1 cells were transiently transfected with small
interfering RNA (siRNA) (150 nM; a pool of 3 target-
specific siRNAs) against SIRT1, or with a nontargeting
control (GeneDireX) in Opti-MEM® I reduced serum
medium containing Lipofectamine RNAiMAX (Invitro-
gen). Transfection efficiency was assessed by western blot.
RNA isolation and quantitative real-time PCR
For gene expression analysis, pairs of tumor and normal
marginal tissues were obtained from 21 OSCCs. The tis-
sues were frozen and stored in liquid nitrogen at −196°C
until use. Total RNA obtained from cultured cells and
human tissue was extracted using TRIzol reagent (Invi-
trogen). cDNA was then reverse-transcribed and ampli-
fied by PCR using a Transcriptor First Strand cDNA
Synthesis kit (Roche Diagnostics, Mannheim, Germany).
Quantitative RT-PCR was jperformed using the FastStart
Universal SYBR Green Master mix (Roche) and an Applied
Biosystems ABI 7900 RealTime PCR System (Applied
Biosystems, Foster City, CA, USA). The oligonucleotide
primers used for human SIRT1, Smad4, MMP7, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
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Gene expression levels were normalized using GAPDH
as an internal reference gene, and the average relative
change was calculated from triplicate or quintuplicate
determinations made by relative quantification, and
applying the delta-delta cycle threshold method. The
protocol for this study was approved by the Institutional
Review Board (IRB) of the Department of Oral and Max-
illofacial Surgery of Chi-Mei Medical, Liouying, Taiwan
(EC-1000202-R1).
Cell chemotactic migration and invasion assay
The chemotactic migration of cells was evaluated using
a 24-well chemotaxis chamber equipped with 8-μm pore
size membranes (Becton-Dickinson labware, Franklin
Lakes, NJ, USA). Cell invasion ability was assessed using
Falcon Cell Culture Inserts with Matrigel (BD). Samples
containing 1 × 105 cells were resuspended in serum-free
medium with 0.1% BSA (Sigma-Aldrich), and then
plated onto the transwell chamber. The chambers were
incubated for 24 h with complete culture medium added
in the lower chamber. Non-mobile cells were removed,
and the chambers were stained with crystal violet. Photo-
micrographs of 5 regions were captured from duplicated
chambers. The numbers of cells were counted and nor-
malized to the control. All experiments were performed in
triplicate and repeated three times.
Cytosolic, nuclear isolation and immunoprecipitation
Cytosolic and nuclear extracts were prepared using a
NE-PER Nuclear and Cytoplasmic Extraction Reagents
kit (Thermo Fisher Scientific, Basingstoke, UK) following
the manufacturer’s protocol. Isolated nuclear extracts were
lysed with RIPA buffer, and then subjected to direct western
blot analysis or immunoprecipitation. Then, 2 mg of pro-
tein from each sample (total lysate or nuclear extract) was
used for immunoprecipitation with a Pierce® Crosslink IP
Kit (Pierce), and the results were analyzed by western blot.
Western blot analysis
Cells were lysed directly in RIPA buffer containing
50 mM Tris–HCl, pH 7.8 150 mM NaCl, 5 mM EDTA,
5 μL/mL Triton X-100, 5 μL/mL Nonidet-P40, 1 μL/mL
sodium deoxycholate, and an EDTA-free complete pro-
tease inhibitor cocktail (Roche; Basel, Switzerland) on
ice for 30 minutes. The lysates were adjusted for protein
concentration with a BCA protein assay kit (Bio-Rad,Hercules, CA, USA). The lysate proteins were resolved
by 10% SDS-PAGE and then transferred to PVDF mem-
branes. The membranes were blocked and incubated
with specific antibodies against SIRT1, E-cadherin,
vimentin, acetylated-lysine (Cell Signaling Technology,
Beverly, MA, USA), actin (Sigma-Aldrich, St. Louis,
USA), N-cadherin (H63), Smad4, MMP7, and GAPDH
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
resolved protein bands were visualized by enhanced
chemiluminescence ECL-Plus detection system (Perkin
Elmer-NEN, France).
Immunohistochemistry
IHC was conducted to detect protein expression in
paraffin-embedded oral squamous cell carcinoma speci-
mens. The slides were stained with rabbit anti-SIRT1
polyclonal antibody (1:25 Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and goat anti-Smad4 polyclonal
antibody (1:100, Santa Cruz Biotechnology) using an
automatic slide stainer BenchMark XT (Ventana Med-
ical Systems; Tucson AZ, USA). Hematoxylin was used
as the counterstain. Two independent pathologists eval-
uated each slide under a light microscope. Immunoreac-
tivity was classified by estimating the percentage (P) of
tumor cells exhibiting characteristic staining (from an
undetectable level, 0%, to homogeneous staining, 100%)
and by estimating the intensity (I) of staining (1, weak
staining; 2, moderate staining; 3, strong staining). Results
were scored by multiplying the percentage of positive
cells by the intensity (i.e. quick score Q = P x I; max-
imum = 300) [98].
In vivo metastasis assay
Six-week-old male CB17-SCID mice (weights 20-25 g)
were anesthetized by intraperitoneal injection with
100 mg/kg ketamine and 10 mg/xylazine. Prior to injec-
tion, human OSCC cell line OECM1-S1 stably expressing
SIRT1 expression plasmid or vector alone was grown to
70% confluence. The OSCC cells were suspended in
RPMI-1640, chilled on ice, and adjusted to a final concen-
tration of 2.5 × 105 cells/mL. For detecting metastasis, we
used an orthotopic floor-of-the mouth murine model
which was monitored for 28 to 42 days. After sacrifice,
the organ and tissues were removed, fixed, paraffin-
embedded, serially sectioned, and subjected to hematoxylin
and eosin (H&E) and IHC staining.
Enzyme activity assay
SIRT1 proteins obtained from total lysates of cultured
cells and human tissue were concentrated using a Pierce®
Crosslink IP Kit (Pierce), according to the manufacturer’s
recommendations. Protein concentrations were determined
using a Bio-Rad protein assay kit (Bio-Rad; Hercules, CA,
USA). SIRT1 enzyme activity was determined using a
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Meeting, PA, USA) according to the manufacturer’s in-
structions. This assay uses a small lysine-acetylated peptide,
corresponding to K382 of human p53, as a substrate. The
lysine residue is deacetylated by SIRT1, and this process is
dependent on addition of exogenous NAD+. The fluores-
cence values obtained in the absence of NAD+ did not
differ from those obtained with the blank. Addition of
exogenous NAD+ was necessary, and this was most
likely because endogenous NAD+ was lost during sam-
ple preparation. The enzyme activity assay for SIRT1
was performed in 50 μL of reaction buffer (Biomol
International, BML-KI286) containing 25 μL of SIRT1
proteins (10 ng/μL), 50 μM Fluor de Lys–SIRT1 sub-
strate, and 500 μM NAD+. Deacetylation reactions were
conducted at 37°C for 60 minutes, and stopped by add-
ing 50 μL of stop solution made by combining Fluor de
Lys Developer (Enzo Life Sciences, Farmingdale, NY,
USA) and 2 mM nicotinamide, followed by incubation
at 37°C for 1 h. Enzyme activity was determined by
spectrophotometric readings made at excitation and
emission wavelengths of 360 nm and 460 nm, respectively,
in endpoint mode, using a SpectraMax M2 microplate
reader (Molecular Devices Corporation, Sunnyvale,
CA, USA). Calculations of net fluorescence were made
after subtracting values for a blank consisting of buffer
without NAD+.MMP7 ELISA and Casein zymography
Total MMP7 concentrations in OSCC cells were
assessed using the Quantikine Human MMP7 Im-
munoassay Kit (R&D Systems, Minneapolis, MN, USA)
according to the manufacturer’s instructions. For ca-
sein zymography, total proteins were loaded on precast
12% Novex zymogram blue casein gels (Invitrogen,
Carlsbad, CA, USA) to measure MMP7 proteolytic
activity. Following electrophoresis, the gels were rena-
tured in Novex Zymogram Renaturing Buffer for 30 -
minutes at room temperature, and then incubated at 37°C
in Novex Zymogram Developing Buffer (Invitrogen) to per-
mit degradation of substrate in the gel matrix. Enzymatic
activity was visualized as a clear band against a blue back-
ground [99,100].Statistical analysis
All data are reported as the mean value ± S.D. obtained
from at least 3 independent experiments. The statistical
significance of differences between means was assessed
by ANOVA. The P values for linear trends of mRNA ex-
pression were analyzed using the t test (slope estimate)
in simple linear regression models. P-values <0.05 and
0.01 (depending on the experiment) were considered sta-
tistically significant.Additional files
Additional file 1: Figure S1. SIRT1 deacetylates Smad4 in HSC3 cell
lines. (A) Ectopic expression of SIRT1 reduces acetylation levels of Smad4.
Equal amounts of proteins (20 ug) from the HSC3 cells were transient
transfected with pEGFP-SIRT1 or vector alone (pEGFP-C1) for 0–48 h and
analyzed by Western blot. (B) Western blotting reveal the expression and
acetylation levels of endogenous Smad4 in HSC3 cell lines were transient
transfected with pEGFP-SIRT1 or vector alone (pEGFP-C1) for 24 h, and
were treated with TGF-β 5 ng/ml for 48 h. Western blots were probed
with SIRT1, acetylated-Lysine (Ac-K) and Smad4.
Additional file 2: Figure S2. SIRT1 represses the expression of MMP-7
by deacetylating Smad4 in HSC3 cell lines. (A) Western blotting reveal the
expression levels of Smad4, MMP-7 and E-cadherin in HSC3 cell lines
were transient transfected with pEGFP-SIRT1 or vector alone (pEGFP-C1)
for 24 h, and were treated with TGF-β 5 ng/ml for 48 h. (B) MMP-7 activities
of SIRT1-overexpressing or mock-transfected HSC3 cells were assayed by
casein zymography after treatment with or without TGF-β 5 ng/ml for 48 h.
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